Head and Neck cancer Market
Key Highlights:
- The Head and Neck Cancer market size in The United States will grow at a CAGR of 8.2% by 2032.
- In 2021, the total Head and Neck Cancer incident cases in the 7MM countries were ~158,000, and these cases are anticipated to increase during the study period.
- The Head and Neck Cancer market size in the 7MM was observed to be of USD 2,801 million in 2021.
Request a sample to unlock the CAGR for Head and Neck Cancer Market.
DelveInsight’s ‘Head and Neck Cancer (HNC) - Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Head and neck cancer (HNC) historical and forecasted epidemiology as well as the Head and neck cancer (HNC) cancer market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Head and Neck Cancer (HNC) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Head and neck cancer (HNC) market size. The report also covers current Head and neck cancer (HNC) treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019–2032
Head and Neck Cancer (HNC) Disease Understanding and Treatment
Head and Neck Cancer (HNC) Cancer Overview
HNC refers to several types of cancers that affect the head and neck areas of the body. These cancers account for approximately 3–5% of all cancers in the US and are common in men and people over the age of 50. These cancers are easily preventable and can be treated if diagnosed early. The most common causes of HNC are tobacco and alcohol use, and nowadays, HPV has also emerged as an important risk factor. HNC usually begins in the squamous cells – often referred to as squamous cell carcinomas of the head and neck – that line the mucosal surfaces of the head and neck for example, those inside the mouth, throat, and voice box. They can also begin in the salivary glands, sinuses, muscles, or nerves, but they are less common than squamous cell carcinomas.
Continued in the report…
Head and Neck Cancer Diagnosis
There are many tests used for diagnosing HNC. The doctor may consider these factors when choosing a diagnostic test:
- The type of cancer suspected
- Signs and symptoms
- Age and general health
- The results of earlier medical tests
If a person has symptoms and signs of HNC, the doctor will take a complete medical history, noting all symptoms and risk factors. In addition, the following tests may be used to diagnose HNC:
Physical examination/blood and urine tests
During a physical examination, the doctor feels for any lumps on the neck, lips, gums, and cheeks. The doctor will also inspect the nose, mouth, throat, and tongue for abnormalities, often using a light and a mirror for a clearer view. Blood tests and urine tests may be done to help diagnose cancer.
Endoscopy
An endoscopy allows the doctor to see inside the body with a thin, lighted, flexible tube called an endoscope. The person may be sedated as the tube is gently inserted through the nose into the throat and down the esophagus to examine the head and neck.
Biopsy
A biopsy removes a small amount of tissue for examination under a microscope. A pathologist then analyzes the sample(s) removed during the biopsy. A common type of biopsy is called fine needle aspiration. This procedure collects cells using a thin needle inserted directly into the tumor or lymph node. The cells are examined under a microscope for cancer cells, called a cytologic examination.
Biomarker testing of the tumor
The doctor may recommend running laboratory tests on a tumor sample to identify specific genes, proteins, and other factors unique to the tumor; also called molecular testing of the tumor, these tests help determine the treatment options.
Continued in the report…
Head and Neck Cancer Treatment
The main treatment options are surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Surgery, radiation therapy, or a combination of these treatments are part of the treatment plan.
Surgery
During surgery, the goal is to remove the cancerous tumor and some surrounding healthy tissue during an operation. Types of surgery for HNC include:
Laser technology - This may be used to treat an early-stage tumor, especially if found in the larynx
Excision - This is an operation to remove the cancerous tumor and some surrounding healthy tissue, known as a margin
Lymph node dissection or neck dissection - If the doctor suspects cancer has spread, the doctor may remove lymph nodes in the neck. This may be done at the same time as an excision
Reconstructive (plastic) surgery - If cancer surgery requires major tissue removal, such as removing the jaw, skin, pharynx, or tongue, reconstructive or plastic surgery may be done to replace the missing tissue.
Continued in the report…..
Head and Neck Cancer Epidemiology
The Head and Neck Cancer epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Head and Neck Cancer, Molecular Alteration-specific Incident Cases of Head and Neck Cancer, and Stage-specific Incident Cases of Head and Neck Cancer, Site-specific Incident Cases of Head and Neck Cancer, HPV-specific Incident Cases of Head and Neck Cancer scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Head and Neck Cancer Key Findings
- In 2021, the total Head and Neck Cancer incident cases in the 7MM countries were ~158,000, and these cases are anticipated to increase during the study period.
- Among the European countries, Germany had the highest number of incident cases of Head and Neck Cancer in 2021, i.e., ~20,000 cases, followed by France which had ~16,000 incident cases in 2021. On the other hand, Italy had the lowest incident cases of Head and Neck Cancer, i.e. ~9900 cases in 2021. Japan had ~20,000 incident cases of HNC in 2021.
- The analysis from 2021 suggests that the stage-specific incident cases of Head and Neck Cancer (HNC) in the US were maximum for regional, at ~30,000 cases, followed by localized with ~21,000 cases, distant with ~11,000 cases, and ~3,000 cases of the unknown stage.
- In 2021, the molecular alteration-specific incident cases of HNC in the US were maximum for TP53 at ~47,000 cases followed by CCND1, PIK3CA, NOTCH1, KMT2D, EGFR, NSD1, FGFR1, and HRAS mutations that had ~18,000 cases; ~14,000 cases; ~12,400 cases; ~12,000 cases; ~10,000 cases; ~6,500 cases; ~5,700 cases; and ~3,300 cases respectively.
- In 2021, the HPV status-specific incident cases of Head and Neck Cancer (HNC) in the US were maximum for HPV negative at ~40,000 cases followed by HPV positive at ~23,000 cases. By 2032, HPV status-specific incident cases of HNC are expected to increase significantly.
Country-Wise Head and Neck Cancer Epidemiology
The epidemiology segment provides the Head and Neck Cancer epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Head and Neck Cancer Drug Chapters
Head and Neck Cancer Emerging Drugs
TECENTRIQ (Atezolizumab): Hoffmann-La Roche
TECENTRIQ (Atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) and aims to prevent cancer immune evasion. A Phase III trial evaluates TECENTRIQ in patients with adjuvant SCCHN (Roche, 2022). Atezolizumab binds to PD-L1 and blocks its interactions with both PD-1 and B7 receptors. This releases the PD-L1/PD-1 mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity (Genentech, 2022). It is under clinical development to treat locally advanced SCCHN as adjuvant therapy.
Products detail in the report…
KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
KEYTRUDA (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. A humanized monoclonal antibody blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect tumor cells and healthy cells. KEYTRUDA is indicated for HNSCC in combination with platinum and fluorouracil (FU) for the first-line treatment of patients with metastatic or unresectable, recurrent HNSCC. As a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test, and as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
Products detail in the report…
XEVINAPANT (debio 1143): Merck KGaA
XEVINAPANT (debio 1143) is a potential first-in-class potent oral antagonist of IAPs (Inhibitor of Apoptosis Proteins) being investigated in the Phase III TrilynX study for previously untreated high-risk locally advanced LA SCCHN, in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy. It prevents the programmed cell death caused by chemoradiotherapy (CRT) and is believed to deprive tumors of one of their major resistance mechanisms, thereby increasing tumor cell sensitivity to CRT.
Products detail in the report…
Toripalimab: Junshi Biosciences/Coherus
Toripalimab is an anti-PD-1 monoclonal antibody developed to block PD-1 interactions with its ligands, PD-L1, and PD-L2, and for enhanced receptor endocytosis function. PD-L1 and PD-L2 are tumor checkpoint proteins that recognize the PD-1 receptor on T-cell and exhaust their anti-tumor activity. Blocking PD-1 interactions with PD-L1 and PD-L2 is thought to recharge the immune system’s ability to attack and kill tumor cells.
Products detail in the report…
Tipifarnib: Kura Oncology
Kura Oncology’s lead drug candidate, tipifarnib, is a potent and highly selective inhibitor of farnesylation, a key cell signaling process in cancer initiation and development. Tipifarnib has been studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets, however, no molecular mechanism of action had previously been determined that could explain its activity across a range of diverse clinical indications, including squamous tumors that carry mutant HRAS, as well as in lymphoid, myeloid and solid tumors that do not carry HRAS mutations.
Products detail in the report…
List to be continued in the report…
Head and Neck Cancer Market Outlook
HNC is a broad indication involving many site-specific cancers, such as laryngeal and hypopharyngeal cancer, nasal cavity and par nasal sinus cancer, nasopharyngeal cancer, oral and or pharyngeal cancer, and salivary gland cancer. Many cancers of the head and neck are curable, especially if detected at an early stage. Although eliminating the cancer is the primary goal of treatment, preserving the function of the nearby nerves, organs, and tissues is also very important. When planning treatment, doctors consider how treatment might affect a person’s quality of life, such as how a person feels, looks, talks, eats, and breathes.
Overall, the treatment approach for Head and Neck Cancer patients can involve multiple options like surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Pharmacological therapies are mainly used to destroy cancer cells, and they are either administered systematically or locally (by a medical oncologist). Pharmacological therapies being administered to a HNC patient can be chemotherapy, targeted therapy, or immunotherapy.
The HNSCC is the sixth most common cancer worldwide. Over 50% of patients with HNSCC are diagnosed with loco regionally advanced (Stage III) disease, whereas newly diagnosed metastatic HNSCC (Stage IVc) is uncommon (4% of newly diagnosed HNSCC). Patients with locoregionally advanced HNSCC typically receive multimodal treatment using surgery or radiation with or without chemotherapy.
Among all the available therapeutic options, chemotherapy is being extensively used in all lines of treatment. Multiple drugs have been identified with the advancement of medical technologies and increased research and development activities. Immunotherapeutic options have also been identified for treating HNC patients.
Continued in the report…..
Head and Neck Cancer Key Findings
- The Head and Neck Cancer market size in the 7MM was observed to be of USD 2,801 million in 2021.
- In 2021, the Head and Neck Cancer market size in the US was of USD 1,831 million. Among the EU-5 countries, Germany had the highest Head and Neck Cancer market size in 2021, i.e., USD 219 million. The lowest Head and Neck Cancer market size was estimated in Italy with USD 114 million in 2021.
- In Japan, the Head and Neck Cancer market size was observed to be of USD 187 million in 2021.
- The Head and Neck Cancer market size in The United States will grow at a CAGR of 8.2% by 2032.
The United States: Head and Neck Cancer Market Outlook
This section provides the total Head and Neck Cancer market size and market size by therapies in the United States.
EU-5: Head and Neck Cancer Market Outlook
The total Head and Neck Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan: Head and Neck Cancer Market Outlook
The total Head and Neck Cancer market size and market size by therapies in Japan are provided.
Head and Neck Cancer Drugs Uptake
This section focuses on the rate of uptake of the potential Head and Neck Cancer drugs recently launched in the market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Head and Neck Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the Head and Neck Cancer drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Head and Neck Cancer Development Activities
The Head and Neck Cancer report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted Head and Neck Cancer therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Head and Neck Cancer emerging therapies.
Reimbursement Scenario in Head and Neck Cancer
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive market Intelligence analysis of the Head and Neck Cancer market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
|
Report Metrics |
Details |
|
Study Period |
2019 to 2032 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2032 |
|
CAGR |
|
|
Market Size |
USD 2801 million in 2021 |
|
Key Companies |
CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly and Company |
Scope of the Head and Neck Cancer Report
- The report covers the descriptive overview of Head and Neck Cancer, explaining its causes, symptoms, pathophysiology, genetic basis, diagnosis, and currently available therapies.
- Comprehensive insight has been provided into the Head and Neck Cancer epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Head and Neck Cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Head and Neck Cancer market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Head and Neck Cancer market.
Head and Neck Cancer Market Report Highlights
- The robust pipeline with novel MOA and oral ROA, increasing prevalence, and effectiveness of drugs will positively drive the Head and Neck Cancer market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Head and Neck Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Head and Neck Cancer. The launch of emerging therapies will significantly impact the Head and Neck Cancer market.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Head and Neck Cancer Report Insights
- Head and Neck Cancer Patient Population
- Head and Neck Cancer Therapeutic Approaches
- Head and Neck Cancer Pipeline Analysis
- Head and Neck Cancer Market Size and Trends
- Head and Neck Cancer Market Opportunities
- Impact of upcoming Head and Neck Cancer Therapies
Head and Neck Cancer Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Head and Neck Cancer Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Head and Neck Cancer Market
- Head and Neck Cancer Drugs Uptake
Head and Neck Cancer Report Assessment
- Current Head and Neck Cancer Treatment Practices
- Head and Neck Cancer Unmet Needs
- Pipeline Product Profiles
- Head and Neck Cancer Market Attractiveness
- SWOT analysis
Key Questions
Head and Neck Cancer Market Insights:
- What was the Head and Neck Cancer market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Head and Neck Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Head and Neck Cancer market size during the forecast period (2022–2032)?
- At what CAGR, the Head and Neck Cancer market is expected to grow at the 7MM level during the forecast period (2022–2032)?
- What would be the Head and Neck Cancer market outlook across the 7MM during the forecast period (2022–2032)?
- What would be the Head and Neck Cancer market growth till 2032 and what will be the resultant market size in the year 2032?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Head and Neck Cancer Epidemiology Insights:
- What are the disease risk, burdens, and unmet needs of Head and Neck Cancer?
- What is the historical Head and Neck Cancer patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Head and Neck Cancer at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Head and Neck Cancer?
- Out of the above-mentioned countries, which country would have the highest population of Head and Neck Cancer during the forecast period (2022–2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Head and Neck Cancer along with the approved therapy?
- What are the current treatment guidelines for the treatment of Head and Neck Cancer?
- What are the Head and Neck Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Head and Neck Cancer?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Head and Neck Cancer?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Head and Neck Cancer therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Head and Neck Cancer and their status?
- What are the key designations that have been granted for the emerging therapies for Head and Neck Cancer?
- What are the 7MM historical and forecasted market of Head and Neck Cancer?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving Head and Neck Cancer.
- To understand the future market competition in the Head and Neck Cancer market and an insightful review of the market.
- Organize sales and marketing efforts by identifying the best opportunities for Head and Neck Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Head and Neck Cancer market.
- To understand the future market competition in the Head and Neck Cancer market.
Frequently Asked Questions
1. Key Insights
2. Report Introduction
3. Head and Neck Cancer (HNC) -Market Overview at a Glance
3.1. Market Share (%) Head and Neck Cancer (HNC) by Therapies in 2019
3.2. Market Share (%) of Head and Neck Cancer (HNC) by Therapies in 2032
4. Head and Neck Cancer (HNC) - Future Prospects
5. Executive Summary of Head and Neck Cancer
5.1. Quick Insights
6. Key Events
7. Disease Background and Overview
7.1. Introduction
7.2. Signs and Symptoms
7.3. Risk Factors and Causes
7.4. Pathophysiology
7.4.1. HPV-negative HNSCC
7.4.2. HPV-positive HNSCC
7.4.3. Genomic alterations and key pathways
7.5. Diagnosis
7.6. Diagnostic Guidelines
7.6.1. Squamous cell carcinoma of the oral cavity, larynx, oropharynx, and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis
7.6.2. Diagnosis of Squamous Cell Carcinoma of Unknown Primary (SCCUP) in the head and neck: ASCO Guideline
8. Treatment and Management
8.1. Treatment Algorithms
8.2. Treatment and Management Guidelines
8.2.1. Squamous cell carcinoma of the oral cavity, larynx, oropharynx, and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for treatment
8.2.2. Management of Squamous Cell Carcinoma of Unknown Primary (SCCUP) in the head and neck: ASCO Guideline
8.2.3. HNC: NCCN Treatment Guidelines
9. Methodology
10. Head and Neck CancerEpidemiology and Patient Population
10.1. Key Findings
10.2. Assumptions and Rationale 7MM
10.3. Total Incident Cases of Head and Neck Cancer (HNC) in the 7MM
10.4. The United States
10.4.1. Total Incident Cases of Head and Neck Cancer (HNC) in the United States
10.4.2. HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the United States
10.4.3. Site-specific Incident Cases of Head and Neck Cancer (HNC) in the United States
10.4.4. Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the United States
10.4.5. Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the United States
10.5. EU-5
10.5.1. Total Incident Cases of Head and Neck Cancer (HNC) in the EU-5
10.5.2. HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5
10.5.3. Site-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5
10.5.4. Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5
10.5.5. Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5
10.6. Japan
10.6.1. Total Incident Cases of Head and Neck Cancer (HNC) in Japan
10.6.2. HPV-specific Incident Cases of Head and Neck Cancer (HNC) in Japan
10.6.3. Site-specific Incident Cases of Head and Neck Cancer (HNC) in Japan
10.6.4. Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in Japan
10.6.5. Stage-specific Incident Cases of Head and Neck Cancer (HNC) in Japan
11. Patient Journey
12. Marketed Products
12.1. Key-cross
13. Emerging Therapies
13.1. Key Cross Competition
13.2. Leukocyte Interleukin (MULTIKINE): CEL-SCI
13.2.1. Product description
13.2.2. Other developmental activities
13.2.3. Clinical developmental activities
13.2.3.1. Clinical trials information
13.2.4. Safety and efficacy
13.3. Toripalimab: Junshi Biosciences/Coherus
13.3.1. Product description
13.3.2. Other developmental activities
13.3.3. Clinical developmental activities
13.3.3.1. Clinical trials information
13.3.4. Safety and efficacy
13.4. Cabozantinib: Exelixis
13.4.1. Product description
13.4.2. Clinical developmental activities
13.4.2.1. Clinical trials information
13.4.3. Safety and efficacy
13.5. Eftilagimod alpha (Efti/IMP321): Immutep S.A.S./Merck Sharp & Dohme LLC
13.5.1. Product description
13.5.2. Other developmental activities
13.5.3. Clinical developmental activities
13.5.3.1. Clinical trials information
13.5.4. Safety and efficacy
13.6. LN-145 (Tumor Infiltrating Lymphocytes): Iovance Biotherapeutics
13.6.1. Product description
13.6.2. Clinical developmental activities
13.6.2.1. Clinical trials information
13.6.3. Safety and efficacy
13.7. Tislelizumab: BeiGene
13.7.1. Product description
13.7.2. Other developmental activities
13.7.3. Clinical developmental activities
13.7.3.1. Clinical trials information
13.7.4. Safety and efficacy
13.8. Penpulimab/AK105: Akeso/Chia Tai-Tianqing
13.8.1. Product description
13.8.2. Other developmental activities
13.8.3. Clinical developmental activities
13.8.3.1. Clinical trials information
13.8.4. Safety and efficacy
13.9. Tipifarnib: Kura Oncology
13.9.1. Product description
13.9.2. Other developmental activities
13.9.3. Clinical developmental activities
13.9.3.1. Clinical trials information
13.9.4. Safety and efficacy
13.10. XEVINAPANT (Debio 1143): Merck KGaA
13.10.1. Product description
13.10.2. Other developmental activities
13.10.3. Clinical developmental activities
13.10.3.1. Clinical trials information
13.10.4. Safety and efficacy
13.11. Penpulimab/AK105: Akeso/Chia Tai-Tianqing
13.11.1. Product description
13.11.2. Other developmental activities
13.11.3. Clinical developmental activities
13.11.3.1. Clinical trials information
13.11.4. Safety and efficacy
13.12. Tipifarnib: Kura Oncology
13.12.1. Product description
13.12.2. Other developmental activities
13.12.3. Clinical developmental activities
13.12.3.1. Clinical trials information
13.12.4. Safety and efficacy
13.13. TECENTRIQ (atezolizumab): Hoffmann-La Roche
13.13.1. Product description
13.13.2. Clinical developmental activities
13.13.2.1. Clinical trials information
13.13.3. Safety and efficacy
13.14. Cyramza (ramucirumab): Eli Lilly and Company
13.14.1. Product description
13.14.2. Other developmental activities
13.14.3. Clinical developmental activities
13.14.3.1. Clinical trials information
13.14.4. Safety and efficacy
14. Head and Neck Cancer (HNC): Seven Major Market Analysis
14.1. Key Findings
14.3. Market Outlook
14.4. Attribute Analysis
14.5. Key Market Forecast Assumptions
14.6. Market size of Head and Neck Cancer (HNC) in the 7MM
14.7. Market size of Head and Neck Cancer (HNC) Cancer by Therapies in the 7MM
14.8. Market size of Head and Neck Cancer (HNC) in the United States
14.8.1. Total Market size of Head and Neck Cancer (HNC)
14.8.2. Market Size of Head and Neck Cancer (HNC) by Therapies
14.8.2.1. Market Size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in the United States
14.8.2.2. Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in the United States
14.8.2.3. Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in the United States
14.9. Market Size of Head and Neck Cancer (HNC) in EU-5
14.9.1. Total Market Size of Head and Neck Cancer (HNC)
14.9.2. Market Size of Head and Neck Cancer (HNC) by Therapies
14.9.2.1. Market Size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in EU-5
14.9.2.2. Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in EU-5
14.9.2.3. Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in EU-5
14.10. Market Size of Head and Neck Cancer (HNC) in Japan
14.10.1. Total Market Size of Head and Neck Cancer (HNC)
14.10.2. Market Size of Head and Neck Cancer (HNC) by Therapies
14.10.2.1. Market Size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in Japan
14.10.2.2. Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in Japan
14.10.2.3. Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in Japan
15. Market Access and Reimbursement
15.1. Reimbursement
15.2. Patient Access Program
16. KOL Views
17. SWOT Analysis
18. Unmet Needs
19. Appendix
19.1. Report Methodology
19.2. Bibliography
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
List of Table
Table 1: Summary of Head and Neck Cancer (HNC) (2019–2032)
Table 2: Key Events
Table 3: Work-up for Staging and Diagnosis
Table 4: NCCN Treatment Guidelines for HNC
Table 5: Total Incident Cases of Head and Neck Cancer (HNC) in the 7MM (2019–2032)
Table 6: Total Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Table 7: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Table 8: Site-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Table 9: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Table 10: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Table 11: Total Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019–2032)
Table 12: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019–2032)
Table 13: Site-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019–2032)
Table 14: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019–2032)
Table 15: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019–2032)
Table 16: Total Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Table 17: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Table 18: Site-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Table 19: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Table 20: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Table 21: ERBITUX (Cetuximab), Clinical Trial Description, 2022
Table 22: Efficacy Results in Locoregionally Advanced SCCHN in BONNER
Table 23: Efficacy Results in Recurrent Locoregional Disease or Metastatic SCCHN in EXTREME
Table 24: OPDIVO (nivolumab), Clinical Trial Description, 2022
Table 25: OS-CheckMate 141
Table 26: KEYTRUDA (pembrolizumab), Clinical Trial Description, 2022
Table 27: Efficacy Results* for KEYTRUDA Plus Platinum/Fluorouracil in KEYNOTE-048
Table 28: Efficacy Results* for KEYTRUDA as a Single Agent in KEYNOTE-048 (CPS ≥1 and CPS ≥20)
Table 29: Key cross competition
Table 30: Leukocyte Interleukin (MULTIKINE), Clinical Trial Description, 2022
Table 31: Toripalimab, Clinical Trial Description, 2022
Table 32: Cabozantinib, Clinical Trial Description, 2022
Table 33: Eftilagimod alpha (Efti/IMP321), Clinical Trial Description, 2022
Table 34: LN-145, Clinical Trial Description, 2022
Table 35: Tislelizumab, Clinical Trial Description, 2022
Table 36: Penpulimab/AK105, Clinical Trial Description, 2022
Table 37: Tipifarnib, Clinical Trial Description, 2022
Table 38: XEVINAPANT (Debio 1143), Clinical Trial Description, 2022
Table 39: AN2025 (buparlisib), Clinical Trial Description, 2022
Table 40: LENVIMA (MK-7902/Lenvatinib), Clinical Trial Description, 2022
Table 41: TECENTRIQ (Atezolizumab), Clinical Trial Description, 2022
Table 42: Cyramza (ramucircumab), Clinical Trial Description, 2022
Table 43: Key Market Forecast Assumptions for ERBITUX (cetuximab)
Table 44: Key Market Forecast Assumptions for OPDIVO (nivolumab)
Table 45: Key Market Forecast Assumptions for KEYTRUDA (pembrolizumab)
Table 46: Key Market Forecast Assumptions for leukocyte interleukin (MULTIKINE)
Table 47: Key Market Forecast Assumptions for toripalimab
Table 48: Key Market Forecast Assumptions for cabozantinib
Table 49: Key Market Forecast Assumptions for Eftilagimod alpha (efti/IMP321)
Table 50: Key Market Forecast Assumptions for LN-145
Table 51: Key Market Forecast Assumptions for tislelizumab (BGB-A317)
Table 52: Key Market Forecast Assumptions for penpulimab
Table 53: Key Market Forecast Assumptions for tipifarnib
Table 54: Key Market Forecast Assumptions for Xevinapant (debio 1143)
Table 55: Key Market Forecast Assumptions for AN2025 (buparlisib)
Table 56: Key Market Forecast Assumptions for LENVIMA (MK-7902/lenvatinib)
Table 57: Key Market Forecast Assumptions for TECENTRIQ (atezolizumab)
Table 58: Key Market Forecast Assumptions for CYRAMZA (ramucirumab)
Table 59: Key Market Forecast Assumptions for CYRAMZA (ramucirumab)
Table 60: Seven Major Market Size of Head and Neck Cancer (HNC), USD Million (2019–2032)
Table 61: Market Size of Head and Neck Cancer (HNC) by Therapies in the 7MM, USD Million (2019–2032)
Table 62: Total Market Size of Head and Neck Cancer (HNC) in the United States, USD Millions (2019–2032)
Table 63: Market Size of Head and Neck Cancer (HNC) by Therapies in the United States, USD Million (2019–2032)
Table 64: Market Size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in the United States, USD Million (2019–2032)
Table 65: Market Size of Head and Neck Cancer (HNC) by Therapies in the United States (First-line), in USD Million (2019–2032)
Table 66: Market Size of Head and Neck Cancer (HNC) Cancer by Therapies (Second-line plus) in the United States, USD Million (2019–2032)
Table 67: Total Market Size of Head and Neck Cancer (HNC) in EU-5, USD Million (2019–2032)
Table 68: Market Size of Head and Neck Cancer (HNC) by therapies in EU-5, in USD Million (2019–2032)
Table 69: Market size of Head and Neck Cancer (HNC) by therapies (Adjuvant/Neo-adjuvant) in EU-5, USD Million (2019–2032)
Table 70: Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in EU-5, USD Million (2019–2032)
Table 71: Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in EU-5, USD Million (2019–2032)
Table 72: Total Market Size of Head and Neck Cancer (HNC) in Japan, USD Millions (2019–2032)
Table 73: Market Size of Head and Neck Cancer (HNC) by Therapies in Japan, USD Million (2019–2032)
Table 74: Market size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in Japan, USD Million (2019–2032)
Table 75: Market size of Head and Neck Cancer (HNC) by Therapies in Japan (First-line), USD Million (2019–2032)
Table 76: Market size of Head and Neck Cancer (HNC) by therapies in Japan (Second-line plus), in USD Million (2019–2032)
List of Figures
Figure 1: HNC Regions
Figure 2: Symptoms of HNC
Figure 3: Progression of HNSCC and key Genetic Events
Figure 4: Development of Carcinogen-associated, HPV-negative HNSCC
Figure 5: HPV Infection of the Tonsil Crypt and Development of HPV-positive HNSCC
Figure 6: Treatment Options in Locally Advanced SCCHN (SEOM Clinical Guidelines)
Figure 7: Algorithm for Treatment Decision-making for Recurrent and/or Metastatic HNSCC
Figure 8: Proposed Treatment Algorithm in the First-line Setting for Patients With Recurrent and/or Metastatic HNSCC
Figure 9: Proposed Treatment Algorithm in the Second-line Setting for Patients With Recurrent and/or Metastatic HNSCC
Figure 10: Proposed Treatment Algorithm for Recurrent and/or Metastatic HNSCC Patients After Exposure to First-line Immunotherapy +/− Chemotherapy
Figure 11: Total Incident Cases of Head and Neck Cancer (HNC) in the 7MM (2019–2032)
Figure 12: Total Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Figure 13: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Figure 14: Site-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Figure 15: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Figure 16: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Figure 17: Total Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019–2032)
Figure 18: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019–2032)
Figure 19: Site-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019–2032)
Figure 20: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019–2032)
Figure 21: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019–2032)
Figure 22: Total Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Figure 23: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Figure 24: Site-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Figure 25: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Figure 26: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Figure 27: Kaplan–Meier Curves for OS in Patients with Recurrent Locoregional Disease or Metastatic SCCHN in EXTREME
Figure 28: OS-CheckMate 141
Figure 29: Kaplan–Meier Curve for OS for KEYTRUDA plus
Figure 30: Kaplan–Meier Curve for OS for KEYTRUDA as
Figure 31: Baseline Demographic and Clinical Characteristics and Efficacy
Figure 32: Market Size of Head and Neck Cancer (HNC), USD Millions (2019–2032)
Figure 33: Market Size of Head and Neck Cancer (HNC) by Therapies in the 7MM, USD Millions (2019–2032)
Figure 34: Total Market Size of Head and Neck Cancer (HNC) in the United States, USD Millions (2019–2032)
Figure 35: Market Size of Head and Neck Cancer (HNC) by Therapies in the United States, USD Million (2019–2032)
Figure 36: Market Size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in the United States, USD Million (2019–2032)
Figure 37: Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in the United States, USD Million (2019–2032)
Figure 38: Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in the United States, in USD Million (2019–2032)
Figure 40: Market Size of Head and Neck Cancer (HNC) by Therapies in EU-5, USD Million (2019–2032)
Figure 41: Market size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in EU-5, USD Million (2019–2032)
Figure 42: Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in EU-5, USD Million (2019–2032)
Figure 43: Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in EU-5, USD Million (2019–2032)
Figure 44: Total Market Size of Head and Neck Cancer (HNC) in Japan, USD Millions (2019–2032)
Figure 45: Market Size of Head and Neck Cancer (HNC) by Therapies in Japan, USD Million (2019–2032)
Figure 46: Market size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in Japan, USD Million (2019–2032)
Figure 47: Market size of Head and Neck Cancer (HNC) by Therapies in Japan (First-line), USD Million (2019–2032)
Figure 48: Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in Japan, USD Million (2019–2032)
Figure 49: Unmet needs
CEL-SCI
Junshi Biosciences
Coherus
Exelixis
Immutep S.A.S.
Merck Sharp & Dohme LLC
Iovance Biotherapeutics
BeiGene
Akeso
Chia Tai-Tianqing
Kura Oncology
Hoffmann-La Roche
Eli Lilly and Company